Jane Wasman bought $34k of SLS
director at SELLAS Life Sciences Group, Inc.. 20,000 shares at an average of $1.69, traded May 30, 2025, filed Jun 2, 2025.
Score components
- +15RoleDirector
- +6Trade size$34k at market
- +10Relative to holdingsHoldings up 192%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-055495, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 30, 2025 | POpen-market purchase Common Stock | +20,000 | $1.69 | $34k | 30,400 | Jun 2, 2025 |
Related signals
Other insiders at SELLAS Life Sciences Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | SLSbuy SELLAS Life Sciences Group, Inc. | Katherine Bach Kalin director | $101k 63,400 shares | +155% | |
| 33Weak | SELLAS Life Sciences Group, Inc. | Robert L Van Nostrand director | $15k 10,000 shares | +96% | |
| 39Weak | SELLAS Life Sciences Group, Inc. | Katherine Bach Kalin director | $36k 20,000 shares | +95% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.